The use of metformin in type 1 diabetes: a systematic review of efficacy

S. Vella, L. Buetow, P. Royle, S. Livingstone, H. M. Colhoun, J. R. Petrie

    Research output: Contribution to journalReview article

    130 Citations (Scopus)

    Abstract

    As adding metformin to insulin therapy has been advocated in type 1 diabetes, we conducted a systematic review of published clinical trials and clinical trial databases to assess the effects on HbA(1c), weight, insulin-dose requirement and adverse effects.

    We constructed evidence tables and fitted a fixed-effects model (inverse variance method) in order to assess heterogeneity between studies and give a crude measure of each overall treatment effect.

    Of 197 studies identified, nine involved randomisation with informed consent of patients with type 1 diabetes to metformin (vs placebo or comparator) in either a parallel or crossover design for at least 1 week. We noted marked heterogeneity in study design, drug dose, age of participants and length of follow-up. Metformin was associated with reductions in: (1) insulin-dose requirement (5.7-10.1 U/day in six of seven studies); (2) HbA(1c) (0.6-0.9% in four of seven studies); (3) weight (1.7-6.0 kg in three of six studies); and (4) total cholesterol (0.3-0.41 mmol/l in three of seven studies). Metformin was well tolerated, albeit with a trend towards increased hypoglycaemia. Formal estimates of combined effects from the five trials which reported appropriate data indicated a significant reduction in insulin dose (6.6 U/day, p < 0.001) but no significant reduction in HbA(1c) (absolute reduction 0.11%, p = 0.42). No reported trials included cardiovascular outcomes.

    Metformin reduces insulin-dose requirement in type 1 diabetes but it is unclear whether this is sustained beyond 1 year and whether there are benefits for cardiovascular and other key clinical outcomes.

    Original languageEnglish
    Pages (from-to)809-820
    Number of pages12
    JournalDiabetologia
    Volume53
    Issue number5
    DOIs
    Publication statusPublished - May 2010

    Keywords

    • Cardiovascular disease
    • HbA(1c)
    • Insulin
    • Metformin
    • Obesity
    • Systematic review
    • Type 1 diabetes
    • Activated protein-kinase
    • Blood-glucose control
    • Subcutaneous insukin
    • Artifical pancreas
    • Overweight patients
    • Glycemic control
    • Metabolic control
    • Double-blind
    • Weight gain
    • Mellitus

    Cite this